Lilly, Hims reach GLP-1 deal; Alnylam sales chief to step down

T2Covered by 1 source · first reported by BioPharma Dive / Healthcare Dive / MedTech Dive at 06 Nov, 13:13 UTC

The deal is part of a course change for Hims, which had previously sold knockoff GLP-1 drugs. Elsewhere, a medicine Servier recently acquired failed a key trial and Ultragenyx announced staff cuts.

science

Sources

• T2Lilly, Hims reach GLP-1 deal; Alnylam sales chief to step downBioPharma Dive / Healthcare Dive / MedTech Dive06 Nov, 13:13